The First European Commission’s Artificial Intelligence Act

By Staff Writer

December 12, 2023

Artificial Intelligence Act European Commission

The European Commission has recently announced a ground-breaking political agreement on the Artificial Intelligence Act (AI Act), marking a historic moment in the field of AI. The AI Act, proposed in April 2021, is the first-ever comprehensive legal framework on Artificial Intelligence worldwide and is set to transpose European values to a new era. The Commission’s President, Ursula von der Leyen, highlighted that AI is already transforming our everyday lives and promises enormous benefits to our economy and society.

The European Approach to Trustworthy AI

The new rules will be applied uniformly across all Member States, following a futureproof definition of AI. The Act adopts a risk-based approach, categorising AI systems into minimal risk, high risk, and unacceptable risk. Minimal risk applications such as AI-enabled recommender systems or spam filters will be free from obligations. High-risk AI systems, including certain critical infrastructures, medical devices, and certain systems used in law enforcement, will have to comply with stringent requirements. AI systems considered a clear threat to people’s fundamental rights will be banned.

The Fines for Non-Adherence

The AI Act has laid out stringent penalties for non-compliance. Companies found violating the rules will be subject to fines. The fines range from €35 million or 7% of global annual turnover (whichever is higher) for violations of banned AI applications, €15 million or 3% for violations of other obligations, and €7.5 million or 1.5% for supplying incorrect information. Small and new businesses will be able to get minor fines that are more fair if they break the AI Act. These fines show the importance of the Act and how vital it is to follow them.

The AI Act and AI for General Purpose

The AI Act establishes explicit regulations for general-purpose AI models, enhancing transparency across the entire value chain. Models that present systemic risks will carry extra legal responsibilities. These include risk management, monitoring significant events, model evaluation, and comparative testing. The Commission, businesses, academia, civil society, and other stakeholders will collaboratively develop these responsibilities into actionable conduct rules. This approach to governing general-purpose AI models demonstrates the Act’s extensive reach. Moreover, it aims to foster the responsible development of AI. 

A first for the world, the new European AI office

The European Commission is launching a new, globally unique European AI Office. This office will enforce new rules at both national and European levels. It will collaborate with national market surveillance officials to ensure correct implementation of the Act. A group of independent science experts will play a crucial role for general purpose models. They will alert about systemic risks and assist in classifying and testing the models. Together with national market surveillance authorities, this new office aims to establish a global standard for AI rules. 

Reference url

Recent Posts

MASLD CKD socioeconomic link
    

Exploring the MASLD CKD Socioeconomic Link

🌍 Are socioeconomic factors influencing your health more than you realise?

Our latest article looks into the intriguing link between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Chronic Kidney Disease (CKD), revealing significant geographical and socioeconomic correlations. Discover how understanding these relationships can inform public health strategies and improve health equity worldwide.

Dive into the findings and implications for health outcomes!

#SyenzaNews #HealthEconomics #globalhealth #HealthcareInnovation

toripalimab nasopharyngeal carcinoma
        

Toripalimab Evidence Journey in Cancer Care

🚀 How did toripalimab become the first immunotherapy approved in the U.S. for nasopharyngeal carcinoma?

The toripalimab evidence journey began with clinical trials in Asia. The JUPITER-02 trial showed toripalimab plus chemotherapy extended median progression-free survival (PFS) to 21.4 months versus 8.2 months with chemotherapy alone

#SyenzaNews #oncology #HealthcareInnovation

blood cancer treatments
        

NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatments in 2024

🚀 The National Institute for Health and Care Excellence (NICE) has made great strides in 2024, reporting a record number of positive recommendations for blood cancer therapies. This pivotal moment not only accelerates patient access to advanced treatments but also highlights the importance of precision medicine in oncology care.

Curious to learn how these advancements are reshaping the healthcare landscape and improving patient outcomes? Explore the full article for insights!

#SyenzaNews #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.